Related Experiment Video
Updated: Apr 4, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS
Published on: November 8, 2015
The biosynthetic pathway of FK506 and its engineering: from past achievements to future prospects
Yeon Hee Ban1, Sung Ryeol Park2, Yeo Joon Yoon3
1Department of Chemistry and Nano Science, Ewha Womans University, Seoul, 120-750, Republic of Korea.
Abstract:
FK506, a 23-membered macrolide produced by several Streptomyces species, is an immunosuppressant widely used to prevent the rejection of transplanted organs. In addition, FK506 and its analogs possess numerous promising therapeutic potentials including antifungal, neuroprotective, and neuroregenerative activities. Herein, we introduce the biological activities and mechanisms of action of FK506 and discuss recent progress made in understanding its biosynthetic pathway, improving production, and in the mutasynthesis of diverse analogs. Perspectives highlighting further strain improvement and structural diversification aimed at generating more analogs with improved pharmaceutical properties will be emphasized.
Related Concept Videos
Drug Biotransformation: Overview
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Amino Acid Biosynthetic Pathways
Bioreactor Controls-III
Production of Pharmaceuticals

